个人中心 - 老虎社区

Hewx

IP属地：未知

帖子 · 15帖子 · 15
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- HewxHewx
  ·2021-06-30
  like pls
  Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>
  The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to
  Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>
  1,951 140
  2
  分享
  举报
- HewxHewx
  ·2021-06-29
  Like pls
  NIO Will Surpass Tesla as China's Top EV Maker, Navellier Says<blockquote>纳维利尔表示，蔚来将超越特斯拉成为中国最大的电动汽车制造商</blockquote>
  NIO (NIO) -Get Report shares rose Monday after Louis Navellier, chief investment officer of money ma
  NIO Will Surpass Tesla as China's Top EV Maker, Navellier Says<blockquote>纳维利尔表示，蔚来将超越特斯拉成为中国最大的电动汽车制造商</blockquote>
  1,636 6
  4
  分享
  举报
- HewxHewx
  ·2021-06-28
  Like pls
  非常抱歉，此主贴已删除
  1,639 3
  7
  分享
  举报
- HewxHewx
  ·2021-06-27
  Pls like
  非常抱歉，此主贴已删除
  1,401 2
  8
  分享
  举报
- HewxHewx
  ·2021-06-26
  Yes back to 300
  非常抱歉，此主贴已删除
  1,381 3
  8
  分享
  举报
- HewxHewx
  ·2021-06-25
  Comment and like please
  Oil Set for Weekly Gain as Focus Turns to Upcoming OPEC+ Meeting<blockquote>随着焦点转向即将举行的OPEC+会议，油价将每周上涨</blockquote>
  (Bloomberg) -- Oil is heading for a fifth weekly advance, the longest winning streak since December,
  Oil Set for Weekly Gain as Focus Turns to Upcoming OPEC+ Meeting<blockquote>随着焦点转向即将举行的OPEC+会议，油价将每周上涨</blockquote>
  1,364 1
  2
  分享
  举报
- HewxHewx
  ·2021-06-24
  Comment and like
  非常抱歉，此主贴已删除
  1,355 1
  2
  分享
  举报
- HewxHewx
  ·2021-06-24
  Comment
  非常抱歉，此主贴已删除
  1,520 评论
  4
  分享
  举报
- HewxHewx
  ·2021-06-24
  Comment
  非常抱歉，此主贴已删除
  1,356 1
  3
  分享
  举报
- HewxHewx
  ·2021-06-23
  Comment and like please
  非常抱歉，此主贴已删除
  1,340 2
  6
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3577008891035439","uuid":"3577008891035439","gmtCreate":1613917773315,"gmtModify":1706620614251,"name":"Hewx","pinyin":"hewx","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.58%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":153825638,"gmtCreate":1625018197224,"gmtModify":1633945791544,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577008891035439","idStr":"3577008891035439"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":140,"repostSize":0,"link":"https://laohu8.com/post/153825638","repostId":"1130740745","repostType":4,"repost":{"id":"1130740745","kind":"news","pubTimestamp":1625017527,"share":"https://www.laohu8.com/m/news/1130740745?lang=zh_CN&edition=full","pubTime":"2021-06-30 09:45","market":"us","language":"en","title":"Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1130740745","media":"AlphaStreet","summary":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to ","content":"<p>  The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.  The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.</p><p><blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote></p><p> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbol<b><i>AVTE</i></b>. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.</p><p><blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为<b><i>AVTE</i></b>.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote></p><p> <b>Cardiopulmonary Research</b></p><p><blockquote><b>心肺研究</b></blockquote></p><p> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.<b>The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.</b></p><p><blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。<b>这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</b></blockquote></p><p> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,<i>AV-101</i>, is an inhaler based on tyrosine kinase inhibitor<i>imatinib</i>. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.</p><p><blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，<i>AV-101</i>，是一种基于酪氨酸激酶抑制剂的吸入剂<i>伊马替尼</i>PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>New-Gen Drug for PAH</b></p><p><blockquote><b>治疗PAH的新一代药物</b></blockquote></p><p> <b>Early-stage clinical trials have indicated that</b><b><i>AV-101</i></b><b>is effective in treating patients suffering from PAH by acting directly on the cause of the disease.</b>In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.</p><p><blockquote><b>早期临床试验表明，</b><b><i>AV-101</i></b><b>通过直接作用于疾病的病因，可有效治疗患有PAH的患者。</b>在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote></p><p> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development of<i>AV-101</i>and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.</p><p><blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发<i>AV-101</i>并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote></p><p> <b>Risks</b></p><p><blockquote><b>风险</b></blockquote></p><p> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.<b>Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely on</b><b><i>AV-101</i></b><b>to become profitable.</b>Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.</p><p><blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。<b>长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于</b><b><i>AV-101</i></b><b>变得有利可图。</b>此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote></p><p> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.</p><p><blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote></p><p></p>","source":"lsy1609745492275","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">AlphaStreet</strong><span class=\"h-time small\">2021-06-30 09:45</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.  The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.</p><p><blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote></p><p> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbol<b><i>AVTE</i></b>. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.</p><p><blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为<b><i>AVTE</i></b>.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote></p><p> <b>Cardiopulmonary Research</b></p><p><blockquote><b>心肺研究</b></blockquote></p><p> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.<b>The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.</b></p><p><blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。<b>这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</b></blockquote></p><p> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,<i>AV-101</i>, is an inhaler based on tyrosine kinase inhibitor<i>imatinib</i>. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.</p><p><blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，<i>AV-101</i>，是一种基于酪氨酸激酶抑制剂的吸入剂<i>伊马替尼</i>PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>New-Gen Drug for PAH</b></p><p><blockquote><b>治疗PAH的新一代药物</b></blockquote></p><p> <b>Early-stage clinical trials have indicated that</b><b><i>AV-101</i></b><b>is effective in treating patients suffering from PAH by acting directly on the cause of the disease.</b>In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.</p><p><blockquote><b>早期临床试验表明，</b><b><i>AV-101</i></b><b>通过直接作用于疾病的病因，可有效治疗患有PAH的患者。</b>在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote></p><p> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development of<i>AV-101</i>and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.</p><p><blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发<i>AV-101</i>并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote></p><p> <b>Risks</b></p><p><blockquote><b>风险</b></blockquote></p><p> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.<b>Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely on</b><b><i>AV-101</i></b><b>to become profitable.</b>Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.</p><p><blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。<b>长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于</b><b><i>AV-101</i></b><b>变得有利可图。</b>此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote></p><p> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.</p><p><blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/\">AlphaStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130740745","content_text":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.\nIn a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.\nCardiopulmonary Research\nThe Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.\nThe company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.\n\nNew-Gen Drug for PAH\nEarly-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.\nProceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.\nRisks\nIt goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.\nBeingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.","news_type":1,"symbols_score_info":{"AVTE":0.9}},"isVote":1,"tweetType":1,"viewCount":1951,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159044756,"gmtCreate":1624933155975,"gmtModify":1633946810711,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577008891035439","idStr":"3577008891035439"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/159044756","repostId":"1195734655","repostType":4,"repost":{"id":"1195734655","kind":"news","pubTimestamp":1624932851,"share":"https://www.laohu8.com/m/news/1195734655?lang=zh_CN&edition=full","pubTime":"2021-06-29 10:14","market":"us","language":"en","title":"NIO Will Surpass Tesla as China's Top EV Maker, Navellier Says<blockquote>纳维利尔表示，蔚来将超越特斯拉成为中国最大的电动汽车制造商</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1195734655","media":"thestreet","summary":"NIO (NIO) -Get Report shares rose Monday after Louis Navellier, chief investment officer of money ma","content":"<p>NIO&nbsp;(<b>NIO</b>) -Get Report&nbsp;shares rose Monday after Louis Navellier, chief investment officer of money manager Navellier, said the Chinese electric-car maker will surpass Tesla&nbsp;(<b>TSLA</b>) -Get Report&nbsp;in China.</p><p><blockquote>蔚来(<b>蔚来</b>)-Get Report周一股价上涨，此前基金管理公司Navellier首席投资官Louis Navellier表示这家中国电动汽车制造商将超越特斯拉(<b>特斯拉</b>）-在中国获取报告。</blockquote></p><p> “Another electric vehicle company will eventually displace Tesla as the biggest manufacturer of EVs in China,” he wrote in a commentary.</p><p><blockquote>“另一家电动汽车公司最终将取代特斯拉成为中国最大的电动汽车制造商，”他在评论中写道。</blockquote></p><p> “I’m talking about NIO. The reality is that this company is on the verge of dominating the EV market in China and Hong Kong.”</p><p><blockquote>“我说的是蔚来。现实情况是，这家公司即将主导中港电动汽车市场。”</blockquote></p><p> NIO American depositary receipts recently traded at $49.23, up 9.2%. They have climbed 27% in the past month amid investor enthusiasm for EVs.</p><p><blockquote>蔚来美国存托凭证近期交易价格为49.23美元，上涨9.2%。由于投资者对电动汽车的热情，过去一个月股价上涨了27%。</blockquote></p><p> Tesla recently traded at $687.47, up 2.3%, and has gained 9% in the past month.</p><p><blockquote>特斯拉近期交易价格为687.47美元，上涨2.3%，过去一个月上涨9%。</blockquote></p><p> As for NIO, “the company boasts that it is the ‘next-generation car company,’ as it designs and manufactures electric vehicles that utilize the latest technologies in connectivity, autonomous driving and artificial intelligence,” Navellier said.</p><p><blockquote>至于蔚来，“该公司自诩为‘下一代汽车公司’，因为它设计和制造的电动汽车采用了连接、自动驾驶和人工智能方面的最新技术，”纳维利尔说。</blockquote></p><p> “The company is also partnering with cutting-edge chip companies like Nvidia&nbsp;(<b>NVDA</b>) -Get Report.”</p><p><blockquote>“该公司还与英伟达等尖端芯片公司合作（<b>NVDA</b>）-获取报告。”</blockquote></p><p> Earlier this month,NIO said that \"Gemini\" was the code namefor a new high-end electric-vehicle lineup to be launched next year. The move buried speculation that the Shanghai EV maker was looking to release a less-expensive mass-entry-level electric car.</p><p><blockquote>本月早些时候，蔚来表示“Gemini”是将于明年推出的新高端电动汽车系列的代号。此举平息了人们的猜测，即这家上海电动汽车制造商正在寻求发布一款更便宜的大众入门级电动汽车。</blockquote></p><p> NIO supplier JAC Group last month invited bids to build a NIO production line code-named “Gemini” that would produce 60,000 units a year. That sparked speculation that it would be a new entry-level NIO model.</p><p><blockquote>蔚来供应商江汽集团上个月招标建造一条代号为“双子座”的蔚来生产线，年产6万辆。这引发了人们对这将是一款新的入门级蔚来车型的猜测。</blockquote></p><p> Also in June,NIO reported a more than 95% year-over-year increasein deliveries for May. Citi analyst Jeff Chung upgraded the stock to buy from neutral while raising his price target to $58.30 from $57.60.</p><p><blockquote>同样在6月份，蔚来公布5月份交付量同比增长超过95%。花旗分析师Jeff Chung将该股评级从中性上调至买入，同时将目标价从57.60美元上调至58.30美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NIO Will Surpass Tesla as China's Top EV Maker, Navellier Says<blockquote>纳维利尔表示，蔚来将超越特斯拉成为中国最大的电动汽车制造商</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNIO Will Surpass Tesla as China's Top EV Maker, Navellier Says<blockquote>纳维利尔表示，蔚来将超越特斯拉成为中国最大的电动汽车制造商</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">thestreet</strong><span class=\"h-time small\">2021-06-29 10:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>NIO&nbsp;(<b>NIO</b>) -Get Report&nbsp;shares rose Monday after Louis Navellier, chief investment officer of money manager Navellier, said the Chinese electric-car maker will surpass Tesla&nbsp;(<b>TSLA</b>) -Get Report&nbsp;in China.</p><p><blockquote>蔚来(<b>蔚来</b>)-Get Report周一股价上涨，此前基金管理公司Navellier首席投资官Louis Navellier表示这家中国电动汽车制造商将超越特斯拉(<b>特斯拉</b>）-在中国获取报告。</blockquote></p><p> “Another electric vehicle company will eventually displace Tesla as the biggest manufacturer of EVs in China,” he wrote in a commentary.</p><p><blockquote>“另一家电动汽车公司最终将取代特斯拉成为中国最大的电动汽车制造商，”他在评论中写道。</blockquote></p><p> “I’m talking about NIO. The reality is that this company is on the verge of dominating the EV market in China and Hong Kong.”</p><p><blockquote>“我说的是蔚来。现实情况是，这家公司即将主导中港电动汽车市场。”</blockquote></p><p> NIO American depositary receipts recently traded at $49.23, up 9.2%. They have climbed 27% in the past month amid investor enthusiasm for EVs.</p><p><blockquote>蔚来美国存托凭证近期交易价格为49.23美元，上涨9.2%。由于投资者对电动汽车的热情，过去一个月股价上涨了27%。</blockquote></p><p> Tesla recently traded at $687.47, up 2.3%, and has gained 9% in the past month.</p><p><blockquote>特斯拉近期交易价格为687.47美元，上涨2.3%，过去一个月上涨9%。</blockquote></p><p> As for NIO, “the company boasts that it is the ‘next-generation car company,’ as it designs and manufactures electric vehicles that utilize the latest technologies in connectivity, autonomous driving and artificial intelligence,” Navellier said.</p><p><blockquote>至于蔚来，“该公司自诩为‘下一代汽车公司’，因为它设计和制造的电动汽车采用了连接、自动驾驶和人工智能方面的最新技术，”纳维利尔说。</blockquote></p><p> “The company is also partnering with cutting-edge chip companies like Nvidia&nbsp;(<b>NVDA</b>) -Get Report.”</p><p><blockquote>“该公司还与英伟达等尖端芯片公司合作（<b>NVDA</b>）-获取报告。”</blockquote></p><p> Earlier this month,NIO said that \"Gemini\" was the code namefor a new high-end electric-vehicle lineup to be launched next year. The move buried speculation that the Shanghai EV maker was looking to release a less-expensive mass-entry-level electric car.</p><p><blockquote>本月早些时候，蔚来表示“Gemini”是将于明年推出的新高端电动汽车系列的代号。此举平息了人们的猜测，即这家上海电动汽车制造商正在寻求发布一款更便宜的大众入门级电动汽车。</blockquote></p><p> NIO supplier JAC Group last month invited bids to build a NIO production line code-named “Gemini” that would produce 60,000 units a year. That sparked speculation that it would be a new entry-level NIO model.</p><p><blockquote>蔚来供应商江汽集团上个月招标建造一条代号为“双子座”的蔚来生产线，年产6万辆。这引发了人们对这将是一款新的入门级蔚来车型的猜测。</blockquote></p><p> Also in June,NIO reported a more than 95% year-over-year increasein deliveries for May. Citi analyst Jeff Chung upgraded the stock to buy from neutral while raising his price target to $58.30 from $57.60.</p><p><blockquote>同样在6月份，蔚来公布5月份交付量同比增长超过95%。花旗分析师Jeff Chung将该股评级从中性上调至买入，同时将目标价从57.60美元上调至58.30美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/nio-to-surpass-tesla-in-china-electric-vehicles-navellier-says\">thestreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉"},"source_url":"https://www.thestreet.com/investing/nio-to-surpass-tesla-in-china-electric-vehicles-navellier-says","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195734655","content_text":"NIO (NIO) -Get Report shares rose Monday after Louis Navellier, chief investment officer of money manager Navellier, said the Chinese electric-car maker will surpass Tesla (TSLA) -Get Report in China.\n“Another electric vehicle company will eventually displace Tesla as the biggest manufacturer of EVs in China,” he wrote in a commentary.\n“I’m talking about NIO. The reality is that this company is on the verge of dominating the EV market in China and Hong Kong.”\nNIO American depositary receipts recently traded at $49.23, up 9.2%. They have climbed 27% in the past month amid investor enthusiasm for EVs.\nTesla recently traded at $687.47, up 2.3%, and has gained 9% in the past month.\nAs for NIO, “the company boasts that it is the ‘next-generation car company,’ as it designs and manufactures electric vehicles that utilize the latest technologies in connectivity, autonomous driving and artificial intelligence,” Navellier said.\n“The company is also partnering with cutting-edge chip companies like Nvidia (NVDA) -Get Report.”\nEarlier this month,NIO said that \"Gemini\" was the code namefor a new high-end electric-vehicle lineup to be launched next year. The move buried speculation that the Shanghai EV maker was looking to release a less-expensive mass-entry-level electric car.\nNIO supplier JAC Group last month invited bids to build a NIO production line code-named “Gemini” that would produce 60,000 units a year. That sparked speculation that it would be a new entry-level NIO model.\nAlso in June,NIO reported a more than 95% year-over-year increasein deliveries for May. Citi analyst Jeff Chung upgraded the stock to buy from neutral while raising his price target to $58.30 from $57.60.","news_type":1,"symbols_score_info":{"NIO":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127843592,"gmtCreate":1624844238016,"gmtModify":1633948101725,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577008891035439","idStr":"3577008891035439"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/127843592","repostId":"1157825898","repostType":4,"isVote":1,"tweetType":1,"viewCount":1639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124833625,"gmtCreate":1624757696267,"gmtModify":1633949059834,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577008891035439","idStr":"3577008891035439"},"themes":[],"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/124833625","repostId":"1172737444","repostType":4,"isVote":1,"tweetType":1,"viewCount":1401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125657176,"gmtCreate":1624672882495,"gmtModify":1633949790039,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577008891035439","idStr":"3577008891035439"},"themes":[],"htmlText":"Yes back to 300","listText":"Yes back to 300","text":"Yes back to 300","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/125657176","repostId":"1164137597","repostType":4,"isVote":1,"tweetType":1,"viewCount":1381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126747726,"gmtCreate":1624586221965,"gmtModify":1633950895331,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577008891035439","idStr":"3577008891035439"},"themes":[],"htmlText":"Comment and like please","listText":"Comment and like please","text":"Comment and like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/126747726","repostId":"1144285047","repostType":4,"repost":{"id":"1144285047","kind":"news","pubTimestamp":1624586033,"share":"https://www.laohu8.com/m/news/1144285047?lang=zh_CN&edition=full","pubTime":"2021-06-25 09:53","market":"us","language":"en","title":"Oil Set for Weekly Gain as Focus Turns to Upcoming OPEC+ Meeting<blockquote>随着焦点转向即将举行的OPEC+会议，油价将每周上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1144285047","media":"Bloomberg","summary":"(Bloomberg) -- Oil is heading for a fifth weekly advance, the longest winning streak since December,","content":"<p>(Bloomberg) -- Oil is heading for a fifth weekly advance, the longest winning streak since December, as stockpiles shrink and the market tightens ahead of an OPEC+ meeting that will consider pumping more crude.</p><p><blockquote>（彭博社）-油价将连续第五周上涨，这是自12月以来最长的连涨，因为库存减少，市场在欧佩克+会议将考虑增加原油产量之前收紧。</blockquote></p><p> Front-month futures in New York are up more than 2% this week and global benchmark Brent is at the highest level since October 2018. The alliance, led by Saudi Arabia and Russia, are set to meet July 1 and the group is widely expected to revive more output in August, according to a Bloomberg survey. Delegates from the coalition say discussions are already underway.</p><p><blockquote>纽约近月期货本周上涨超过2%，全球基准布伦特原油价格处于2018年10月以来的最高水平。根据彭博社的一项调查，由沙特阿拉伯和俄罗斯领导的该联盟定于7月1日举行会议，人们普遍预计该组织将在8月份恢复更多产量。该联盟的代表表示，讨论已经在进行中。</blockquote></p><p> The rebound in fuel consumption in key regions including the U.S. and Europe is rapidly draining stockpiles, with some flagging the possibility of benchmark Brent crude hitting $100 a barrel again. The prospect of an imminent surge of Iranian oil is also diminishing as talks to revive a nuclear deal drag on.</p><p><blockquote>包括美国和欧洲在内的关键地区燃料消费的反弹正在迅速耗尽库存，一些人表示基准布伦特原油有可能再次触及每桶100美元。随着恢复核协议的谈判拖延，伊朗石油即将飙升的前景也在减弱。</blockquote></p><p> The prompt timespread for Brent was 75 cents in backwardation -- where near-dated contracts are more expensive than later-dated ones. The bullish structure has eased from 85 cents at the start of the week.</p><p><blockquote>布伦特原油的即时价差为75美分的现货溢价，即近期合约比近期合约更贵。看涨结构较周初的85美分有所缓解。</blockquote></p><p> Russia is considering making a proposal that OPEC+ boost output and delegates say a hike is being informally discussed. The average gain forecast by analysts was for about 550,000 barrels a day -- barely a quarter of the global supply deficit that the alliance anticipates during August.</p><p><blockquote>俄罗斯正在考虑提出欧佩克+提高产量的提议，代表们表示正在非正式讨论增产问题。分析师预测的平均涨幅约为每天55万桶，仅为该联盟预计8月份全球供应缺口的四分之一。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Set for Weekly Gain as Focus Turns to Upcoming OPEC+ Meeting<blockquote>随着焦点转向即将举行的OPEC+会议，油价将每周上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Set for Weekly Gain as Focus Turns to Upcoming OPEC+ Meeting<blockquote>随着焦点转向即将举行的OPEC+会议，油价将每周上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-25 09:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Oil is heading for a fifth weekly advance, the longest winning streak since December, as stockpiles shrink and the market tightens ahead of an OPEC+ meeting that will consider pumping more crude.</p><p><blockquote>（彭博社）-油价将连续第五周上涨，这是自12月以来最长的连涨，因为库存减少，市场在欧佩克+会议将考虑增加原油产量之前收紧。</blockquote></p><p> Front-month futures in New York are up more than 2% this week and global benchmark Brent is at the highest level since October 2018. The alliance, led by Saudi Arabia and Russia, are set to meet July 1 and the group is widely expected to revive more output in August, according to a Bloomberg survey. Delegates from the coalition say discussions are already underway.</p><p><blockquote>纽约近月期货本周上涨超过2%，全球基准布伦特原油价格处于2018年10月以来的最高水平。根据彭博社的一项调查，由沙特阿拉伯和俄罗斯领导的该联盟定于7月1日举行会议，人们普遍预计该组织将在8月份恢复更多产量。该联盟的代表表示，讨论已经在进行中。</blockquote></p><p> The rebound in fuel consumption in key regions including the U.S. and Europe is rapidly draining stockpiles, with some flagging the possibility of benchmark Brent crude hitting $100 a barrel again. The prospect of an imminent surge of Iranian oil is also diminishing as talks to revive a nuclear deal drag on.</p><p><blockquote>包括美国和欧洲在内的关键地区燃料消费的反弹正在迅速耗尽库存，一些人表示基准布伦特原油有可能再次触及每桶100美元。随着恢复核协议的谈判拖延，伊朗石油即将飙升的前景也在减弱。</blockquote></p><p> The prompt timespread for Brent was 75 cents in backwardation -- where near-dated contracts are more expensive than later-dated ones. The bullish structure has eased from 85 cents at the start of the week.</p><p><blockquote>布伦特原油的即时价差为75美分的现货溢价，即近期合约比近期合约更贵。看涨结构较周初的85美分有所缓解。</blockquote></p><p> Russia is considering making a proposal that OPEC+ boost output and delegates say a hike is being informally discussed. The average gain forecast by analysts was for about 550,000 barrels a day -- barely a quarter of the global supply deficit that the alliance anticipates during August.</p><p><blockquote>俄罗斯正在考虑提出欧佩克+提高产量的提议，代表们表示正在非正式讨论增产问题。分析师预测的平均涨幅约为每天55万桶，仅为该联盟预计8月份全球供应缺口的四分之一。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/oil-set-weekly-gain-focus-233523836.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-set-weekly-gain-focus-233523836.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144285047","content_text":"(Bloomberg) -- Oil is heading for a fifth weekly advance, the longest winning streak since December, as stockpiles shrink and the market tightens ahead of an OPEC+ meeting that will consider pumping more crude.\nFront-month futures in New York are up more than 2% this week and global benchmark Brent is at the highest level since October 2018. The alliance, led by Saudi Arabia and Russia, are set to meet July 1 and the group is widely expected to revive more output in August, according to a Bloomberg survey. Delegates from the coalition say discussions are already underway.\nThe rebound in fuel consumption in key regions including the U.S. and Europe is rapidly draining stockpiles, with some flagging the possibility of benchmark Brent crude hitting $100 a barrel again. The prospect of an imminent surge of Iranian oil is also diminishing as talks to revive a nuclear deal drag on.\nThe prompt timespread for Brent was 75 cents in backwardation -- where near-dated contracts are more expensive than later-dated ones. The bullish structure has eased from 85 cents at the start of the week.\nRussia is considering making a proposal that OPEC+ boost output and delegates say a hike is being informally discussed. The average gain forecast by analysts was for about 550,000 barrels a day -- barely a quarter of the global supply deficit that the alliance anticipates during August.","news_type":1,"symbols_score_info":{"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128912757,"gmtCreate":1624497917979,"gmtModify":1634005259849,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577008891035439","idStr":"3577008891035439"},"themes":[],"htmlText":"Comment and like","listText":"Comment and like","text":"Comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/128912757","repostId":"1193698944","repostType":4,"isVote":1,"tweetType":1,"viewCount":1355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128916720,"gmtCreate":1624497895660,"gmtModify":1634005260549,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577008891035439","idStr":"3577008891035439"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128916720","repostId":"1135246082","repostType":4,"isVote":1,"tweetType":1,"viewCount":1520,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128918070,"gmtCreate":1624497838190,"gmtModify":1634005262438,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577008891035439","idStr":"3577008891035439"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/128918070","repostId":"1115102727","repostType":4,"isVote":1,"tweetType":1,"viewCount":1356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123803626,"gmtCreate":1624414136765,"gmtModify":1634006458592,"author":{"id":"3577008891035439","authorId":"3577008891035439","name":"Hewx","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577008891035439","idStr":"3577008891035439"},"themes":[],"htmlText":"Comment and like please","listText":"Comment and like please","text":"Comment and like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/123803626","repostId":"1115637073","repostType":4,"isVote":1,"tweetType":1,"viewCount":1340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}